HGEN News and Press, Humanigen Inc. From 04/15/20

Company to Begin Enrolling Patients as Soon as Possible at Several Leading Centers Phase III study enrollment to focus on adult, hospitalized patients with COVID-19 pneumonia and at high risk of progression to respiratory failure US multi-center, randomized, placebo-controlled, do...

FDA signs off on Emergency Use Authorization for Humanigen's ( OTCQB:HGEN ) lenzilumab for compassionate use for preventing and treating cytokine storm in severely ill COVID-19 patients. More news on: Humanigen, Inc., Applied Therapeutics, Inc., Humana Inc., Healthcare stocks news, Stock...

Company Provides Drug Free of Charge to Several Leading Centers Lenzilumab neutralizes granulocyte macrophage colony stimulating factor (GM-CSF) a key cytokine in the initiation of cytokine storm GM-CSF is up-stream of interleukin-6 (IL-6) in the development of cytokine storm...

Study to Tackle Leading Cause of Death in COVID-19 Patients Lenzilumab, a monoclonal antibody that neutralizes granulocyte macrophage colony stimulating factor (GM-CSF) GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response leading to acute respiratory...

Humanigen ( OTCQB:HGEN ) has submitted a protocol synopsis to the FDA related to its planned Phase 3 study of lenzilumab for the prevention and treatment of cytokine storm in COVID-19 patients. More news on: Humanigen, Inc., Hoth Therapeutics, Inc., Allogene Therapeutics, Inc., Healthcar...

Study to Tackle Leading Cause of Death in COVID-19 Patients Lenzilumab is a monoclonal antibody that neutralizes GM-CSF, a cytokine up-regulated in COVID-19 patients that can cause a harmful immune response leading to acute respiratory distress syndrome (ARDS) Clinical evidence su...

David J. Kovacs to Organize Public Policy Initiatives Involving Coronavirus BURLINGAME, CA / ACCESSWIRE / March 24, 2020 / Humanigen, Inc., (HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company's...

Ultra-thinly traded micro cap Humanigen ( OTCQB:HGEN   +156% ) rockets up on a 16x surge in volume, a scant 67K shares, in response to its proposed plan to conduct a Phase 3 clinical trial evaluating lead drug lenzilumab for the prevention and treatment of cytokine storm (potentially ...

Study to Tackle Leading Cause of Death in COVID-19 Patients Lenzilumab is a monoclonal antibody that neutralizes GM-CSF, a cytokine up-regulated in COVID-19 patients that can cause a harmful immune response Clinical evidence suggests that this response contributes to cytokine storm c...

Coronavirus triggers cytokine storm in infected patients resulting in severe lung damage and death Lenzilumab is in clinical studies for prevention of cytokine storm BURLINGAME, CA / ACCESSWIRE / March 9, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage bio...